Work

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) – An ACCRU Network study

Year: 2018

Type: article

Abstract: Introduction: Regorafenib (Rego) confers a survival benefit in refractory mCRC patients (pts). Toxicities such as palmar-plantar erythrodysesthesia syndrome (PPES) have limited its use. Despite absence of supportive data, various dosing variations are used in clinical practice.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy149.013

Authors: T. Bekaii-Saab, F. Ou, D. Anderson, D. Ahn, P. Boland, K. Ciombor, N. Jacobs, R. Desnoyers, J. Cleary, J. Meyers, E. Chiorean, K. Pedersen, A. Barzi, J. Sloan, J. McCune, M. Lacouture, H. Lenz, A. Grothey

Institutions: Mayo Clinic, Mayo Clinic in Arizona, HealthPartners, Roswell Park Comprehensive Cancer Center, Vanderbilt University, Wake Forest University, Dana-Farber Cancer Institute, University of Washington, University of Southern California, City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, USC Norris Comprehensive Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2809103470

FWCI: 0.338

Cites:

Cited by: 6

Related to: 10